Galenical formulation of toloxatone

Details Galenical formulation of toloxatone Galenical formulation of toloxatone

1983-07-29

1987-10-13

Friedman, Stanley J.

Drug, bio-affecting and body treating compositions

Lymphokine

A61K 3178

Patent

active

046997822

ABSTRACT:
A new formulation for the oral administration of Toloxatone, an anti-depressant, contains 400 to 600 mg of Toloxatone per unit dose. Such a high Toloxatone content is possible due to the discovery that Toloxatone is competitive with Tyramine towards the A form of a monomine oxidase, and thus does not cause hypertensive crisis. The anti-depressant composition of this invention can therefore be administered to the patient even when Tyramine is present in the patient's system.

REFERENCES:
The Lancet, Oct. 26, 1983 edition, pp. 849 through 851.
Remington's Pharmaceutical Sciences, 16th Edition, pp. 1040 through 1042.
Physician's Desk Reference, pp. 1374, 1375, 1512, 1513, 1684 and 1685.
Vidal, pp. 778, 873, 879 and 1357.

Affiliated with

Also associated with

Rating

Galenical formulation of toloxatone does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Galenical formulation of toloxatone, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Galenical formulation of toloxatone will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-410432